Annual Total Expenses
$14.12 M
+$2.01 M+16.61%
December 31, 2022
Summary
- As of February 21, 2025, NAVB annual total expenses is $14.12 million, with the most recent change of +$2.01 million (+16.61%) on December 31, 2022.
- During the last 3 years, NAVB annual total expenses has risen by +$3.13 million (+28.46%).
- NAVB annual total expenses is now -68.22% below its all-time high of $44.42 million, reached on December 31, 2007.
Performance
NAVB Total Expenses Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Quarterly Total Expenses
$2.13 M
-$296.40 K-12.21%
September 30, 2023
Summary
- As of February 21, 2025, NAVB quarterly total expenses is $2.13 million, with the most recent change of -$296.40 thousand (-12.21%) on September 30, 2023.
- Over the past year, NAVB quarterly total expenses has dropped by -$296.40 thousand (-12.21%).
- NAVB quarterly total expenses is now -94.34% below its all-time high of $37.68 million, reached on December 31, 2007.
Performance
NAVB Quarterly Total Expenses Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Total Expenses Formula
Total Expenses = Cost of Goods Sold + Operating Expenses + Non Operating Expenses
NAVB Total Expenses Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly |
|---|---|---|
| 1 y1 year | +16.6% | -12.2% |
| 3 y3 years | +28.5% | -12.2% |
| 5 y5 years | +0.9% | -12.2% |
NAVB Total Expenses Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | |
|---|---|---|---|---|---|
| 3 y | 3-year | at high | +16.6% | -57.0% | at low |
| 5 y | 5-year | at high | +30.4% | -57.0% | at low |
| alltime | all time | -68.2% | +355.4% | -94.3% | +161.8% |
Navidea Biopharmaceuticals Total Expenses History
| Date | Annual | Quarterly |
|---|---|---|
| Sep 2023 | - | $2.13 M(-12.2%) |
| Jun 2023 | - | $2.43 M(+0.2%) |
| Mar 2023 | - | $2.42 M(-24.3%) |
| Dec 2022 | $14.12 M(+16.6%) | $3.20 M(-35.5%) |
| Sep 2022 | - | $4.96 M(+69.3%) |
| Jun 2022 | - | $2.93 M(-1.7%) |
| Mar 2022 | - | $2.98 M(-18.2%) |
| Dec 2021 | $12.11 M(+11.8%) | $3.64 M(+49.7%) |
| Sep 2021 | - | $2.43 M(-9.4%) |
| Jun 2021 | - | $2.68 M(-20.0%) |
| Mar 2021 | - | $3.35 M(+16.1%) |
| Dec 2020 | $10.83 M(-1.4%) | $2.89 M(-0.6%) |
| Sep 2020 | - | $2.91 M(+23.7%) |
| Jun 2020 | - | $2.35 M(-12.5%) |
| Mar 2020 | - | $2.69 M(-3.2%) |
| Dec 2019 | $10.99 M(-1.6%) | $2.77 M(-10.2%) |
| Sep 2019 | - | $3.09 M(+14.9%) |
| Jun 2019 | - | $2.69 M(+10.3%) |
| Mar 2019 | - | $2.44 M(+9.0%) |
| Dec 2018 | $11.17 M(-20.1%) | $2.24 M(-40.3%) |
| Sep 2018 | - | $3.74 M(+39.2%) |
| Jun 2018 | - | $2.69 M(+7.6%) |
| Mar 2018 | - | $2.50 M(-29.2%) |
| Dec 2017 | $13.99 M(-7.5%) | $3.53 M(+47.9%) |
| Sep 2017 | - | $2.39 M(-51.6%) |
| Jun 2017 | - | $4.92 M(+56.4%) |
| Mar 2017 | - | $3.15 M(-26.3%) |
| Dec 2016 | $15.12 M(-29.5%) | $4.27 M(+56.2%) |
| Sep 2016 | - | $2.73 M(-19.8%) |
| Jun 2016 | - | $3.41 M(-27.6%) |
| Mar 2016 | - | $4.71 M(-236.4%) |
| Dec 2015 | $21.45 M(-36.7%) | -$3.45 M(-141.6%) |
| Sep 2015 | - | $8.30 M(+24.3%) |
| Jun 2015 | - | $6.68 M(-32.7%) |
| Mar 2015 | - | $9.92 M(+48.7%) |
| Dec 2014 | $33.91 M(-14.3%) | $6.67 M(-12.3%) |
| Sep 2014 | - | $7.61 M(-26.0%) |
| Jun 2014 | - | $10.29 M(+10.3%) |
| Mar 2014 | - | $9.33 M(-31.3%) |
| Dec 2013 | $39.57 M(+41.0%) | $13.59 M(+31.6%) |
| Sep 2013 | - | $10.33 M(+19.3%) |
| Jun 2013 | - | $8.65 M(+23.5%) |
| Mar 2013 | - | $7.00 M(-0.4%) |
| Dec 2012 | $28.07 M(+13.6%) | $7.03 M(-22.4%) |
| Sep 2012 | - | $9.07 M(+66.5%) |
| Jun 2012 | - | $5.45 M(-16.4%) |
| Mar 2012 | - | $6.52 M(-27.9%) |
| Dec 2011 | $24.70 M(+85.8%) | $9.04 M(+34.4%) |
| Sep 2011 | - | $6.73 M(+87.3%) |
| Jun 2011 | - | $3.59 M(-32.7%) |
| Mar 2011 | - | $5.34 M(+50.2%) |
| Dec 2010 | $13.29 M(+17.2%) | $3.55 M(-5.7%) |
| Sep 2010 | - | $3.77 M(+8.7%) |
| Jun 2010 | - | $3.47 M(-21.5%) |
| Mar 2010 | - | $4.42 M(+54.2%) |
| Dec 2009 | $11.34 M(+12.3%) | $2.86 M(-1.6%) |
| Sep 2009 | - | $2.91 M(+8.6%) |
| Jun 2009 | - | $2.68 M(-7.1%) |
| Mar 2009 | - | $2.89 M(+46.3%) |
| Dec 2008 | $10.10 M | $1.97 M(-40.5%) |
| Sep 2008 | - | $3.32 M(+22.4%) |
| Jun 2008 | - | $2.71 M(+29.1%) |
| Date | Annual | Quarterly |
|---|---|---|
| Mar 2008 | - | $2.10 M(-94.4%) |
| Dec 2007 | $44.42 M(+367.0%) | $37.68 M(+1715.9%) |
| Sep 2007 | - | $2.08 M(-6.8%) |
| Jun 2007 | - | $2.23 M(-8.6%) |
| Mar 2007 | - | $2.44 M(-12.8%) |
| Dec 2006 | $9.51 M(-0.5%) | $2.79 M(+21.7%) |
| Sep 2006 | - | $2.30 M(+15.0%) |
| Jun 2006 | - | $2.00 M(-17.6%) |
| Mar 2006 | - | $2.42 M(-0.0%) |
| Dec 2005 | $9.56 M(+20.3%) | $2.42 M(+4.1%) |
| Sep 2005 | - | $2.33 M(-16.1%) |
| Jun 2005 | - | $2.77 M(+36.1%) |
| Mar 2005 | - | $2.04 M(-4.4%) |
| Dec 2004 | $7.95 M(-2.1%) | $2.13 M(+10.6%) |
| Sep 2004 | - | $1.93 M(-1.5%) |
| Jun 2004 | - | $1.96 M(+1.0%) |
| Mar 2004 | - | $1.94 M(-19.7%) |
| Dec 2003 | $8.12 M(+2.3%) | $2.41 M(+37.0%) |
| Sep 2003 | - | $1.76 M(-9.0%) |
| Jun 2003 | - | $1.94 M(-3.8%) |
| Mar 2003 | - | $2.01 M(+7.5%) |
| Dec 2002 | $7.94 M(+3.7%) | $1.87 M(-7.1%) |
| Sep 2002 | - | $2.01 M(-6.3%) |
| Jun 2002 | - | $2.15 M(+12.6%) |
| Mar 2002 | - | $1.91 M(+0.6%) |
| Dec 2001 | $7.66 M(-5.0%) | $1.90 M(+6.3%) |
| Sep 2001 | - | $1.79 M(-16.2%) |
| Jun 2001 | - | $2.13 M(+33.8%) |
| Mar 2001 | - | $1.59 M(-24.7%) |
| Dec 2000 | $8.06 M(-42.5%) | $2.12 M(+11.9%) |
| Sep 2000 | - | $1.89 M(-11.9%) |
| Jun 2000 | - | $2.15 M(+12.3%) |
| Mar 2000 | - | $1.91 M(-36.3%) |
| Dec 1999 | $14.03 M(-59.1%) | - |
| Jun 1999 | - | $3.00 M(-9.1%) |
| Mar 1999 | - | $3.30 M(-76.4%) |
| Dec 1998 | $34.30 M(+5.9%) | $14.00 M(+154.6%) |
| Sep 1998 | - | $5.50 M(-6.8%) |
| Jun 1998 | - | $5.90 M(-28.0%) |
| Mar 1998 | - | $8.20 M(-18.8%) |
| Dec 1997 | $32.39 M(+31.7%) | $10.09 M(+46.3%) |
| Sep 1997 | - | $6.90 M(-21.6%) |
| Jun 1997 | - | $8.80 M(+35.4%) |
| Mar 1997 | - | $6.50 M(-21.7%) |
| Dec 1996 | $24.60 M(+98.4%) | $8.30 M(+16.9%) |
| Sep 1996 | - | $7.10 M(+26.8%) |
| Jun 1996 | - | $5.60 M(+33.3%) |
| Mar 1996 | - | $4.20 M(+16.7%) |
| Dec 1995 | $12.40 M(-2.4%) | $3.60 M(+20.0%) |
| Sep 1995 | - | $3.00 M(0.0%) |
| Jun 1995 | - | $3.00 M(-6.3%) |
| Mar 1995 | - | $3.20 M(-27.3%) |
| Dec 1994 | $12.70 M(+53.0%) | $4.40 M(+41.9%) |
| Sep 1994 | - | $3.10 M(+34.8%) |
| Jun 1994 | - | $2.30 M(-14.8%) |
| Mar 1994 | - | $2.70 M(+8.0%) |
| Dec 1993 | $8.30 M(+167.7%) | $2.50 M(+8.7%) |
| Sep 1993 | - | $2.30 M(+9.5%) |
| Jun 1993 | - | $2.10 M(+50.0%) |
| Mar 1993 | - | $1.40 M(+16.7%) |
| Dec 1992 | $3.10 M | $1.20 M(+33.3%) |
| Sep 1992 | - | $900.00 K |
FAQ
- What is Navidea Biopharmaceuticals annual total expenses?
- What is the all time high annual total expenses for Navidea Biopharmaceuticals?
- What is Navidea Biopharmaceuticals annual total expenses year-on-year change?
- What is Navidea Biopharmaceuticals quarterly total expenses?
- What is the all time high quarterly total expenses for Navidea Biopharmaceuticals?
- What is Navidea Biopharmaceuticals quarterly total expenses year-on-year change?
What is Navidea Biopharmaceuticals annual total expenses?
The current annual total expenses of NAVB is $14.12 M
What is the all time high annual total expenses for Navidea Biopharmaceuticals?
Navidea Biopharmaceuticals all-time high annual total expenses is $44.42 M
What is Navidea Biopharmaceuticals annual total expenses year-on-year change?
Over the past year, NAVB annual total expenses has changed by +$2.01 M (+16.61%)
What is Navidea Biopharmaceuticals quarterly total expenses?
The current quarterly total expenses of NAVB is $2.13 M
What is the all time high quarterly total expenses for Navidea Biopharmaceuticals?
Navidea Biopharmaceuticals all-time high quarterly total expenses is $37.68 M
What is Navidea Biopharmaceuticals quarterly total expenses year-on-year change?
Over the past year, NAVB quarterly total expenses has changed by -$296.40 K (-12.21%)